KLCM Advisors Inc. trimmed its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 2.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 829,671 shares of the company's stock after selling 21,465 shares during the quarter. Kenvue comprises 2.1% of KLCM Advisors Inc.'s portfolio, making the stock its 11th biggest holding. KLCM Advisors Inc.'s holdings in Kenvue were worth $17,713,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State Street Corp boosted its position in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock valued at $2,942,458,000 after buying an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Kenvue by 8.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares during the last quarter. Holocene Advisors LP increased its position in Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company's stock worth $321,194,000 after purchasing an additional 5,975,392 shares during the period. M&G PLC raised its holdings in Kenvue by 538.0% during the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company's stock worth $99,847,000 after purchasing an additional 3,660,730 shares during the last quarter. Finally, FMR LLC lifted its position in Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company's stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.
Analyst Ratings Changes
KVUE has been the subject of several analyst reports. Piper Sandler upgraded shares of Kenvue from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Barclays lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and cut their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, UBS Group decreased their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $23.00.
View Our Latest Analysis on Kenvue
Kenvue Stock Performance
KVUE traded up $0.11 during trading hours on Thursday, reaching $22.38. The company's stock had a trading volume of 19,044,773 shares, compared to its average volume of 13,433,218. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The firm has a market cap of $42.90 billion, a PE ratio of 42.22, a price-to-earnings-growth ratio of 2.57 and a beta of 1.45. The company's 50-day moving average is $21.29 and its 200-day moving average is $22.14. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.66%. The ex-dividend date is Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
